

# The Prevalence and Prognosis of Resistant Hypertension

PLoS ONE

9, e114958

DOI: [10.1371/journal.pone.0114958](https://doi.org/10.1371/journal.pone.0114958)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Comparative risk of renal, cardiovascular, and mortality outcomes in controlled, uncontrolled resistant, and nonresistant hypertension. <i>Kidney International</i> , 2015, 88, 622-632.	2.6	146
2	Fisetin protects H9c2 cardiomyoblast cells against H <sub>2</sub> O <sub>2</sub> -induced apoptosis through Akt and ERK1/2 signaling pathways. <i>Molecular and Cellular Toxicology</i> , 2018, 14, 183-192.	0.8	2
3	Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association. <i>Hypertension</i> , 2018, 72, e53-e90.	1.3	629
4	Heart Failure and Frailty in the Community-Living Elderly Population: What the UFO Study Will Tell Us. <i>Frontiers in Physiology</i> , 2018, 9, 347.	1.3	5
5	Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): results in the pre-specified subgroup with heart failure. <i>European Journal of Heart Failure</i> , 2020, 22, 1462-1471.	2.9	27
6	Heart Failure with Preserved Ejection Fraction—a Concise Review. <i>Current Cardiology Reports</i> , 2020, 22, 82.	1.3	40
7	Contemporary Strategies to Manage High Blood Pressure in Patients with Coexistent Resistant Hypertension and Heart Failure With Reduced Ejection Fraction. <i>Cardiology and Therapy</i> , 2021, 10, 9-25.	1.1	1
8	Sacubitril/valsartan for heart failure with preserved ejection fraction and resistant hypertension: one shot for a double strike?. <i>European Heart Journal</i> , 2021, 42, 3753-3755.	1.0	9
9	Sacubitril-valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction. <i>European Heart Journal</i> , 2021, 42, 3741-3752.	1.0	74
10	Resistance to antihypertensive treatment and long-term risk: The Atherosclerosis Risk in Communities study. <i>Journal of Clinical Hypertension</i> , 2021, 23, 1887-1896.	1.0	7
11	İlinical and anamnestic features and their prognostic value in assessment of treatment efficiency of arterial hypertension with comorbidity. <i>Patoloji</i> , 2018, .	0.1	2
13	Apparent Treatment-Resistant Hypertension Across the Spectrum of Heart Failure Phenotypes in the Swedish HF Registry. <i>JACC: Heart Failure</i> , 2022, 10, 380-392.	1.9	5
14	Microvascular Dysfunction in Heart Failure with Preserved Ejection Fraction: Pathophysiology, Assessment, Prevalence and Prognosis. <i>Cardiac Failure Review</i> , 0, 8, .	1.2	12
15	Diastolic Dysfunction and Heart Failure With Preserved Ejection Fraction In Patients With Resistant Hypertension and Type 2 Diabetes Mellitus. <i>Kardiologiya</i> , 2022, 62, 11-18.	0.3	0
16	What is resistant arterial hypertension?. <i>Blood Pressure</i> , 2023, 32, .	0.7	10
17	Denervation or stimulation? Role of sympatho-vagal imbalance in HFpEF with hypertension. <i>Hypertension Research</i> , 2023, 46, 1727-1737.	1.5	7